Comparing Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion

Affiliations

¹ Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts2Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts3CME Editor, JAMA Ophthalmology.

Comment

Jennifer K Sun. JAMA Ophthalmol. 2017.

. 2017 Jun 1;135(6):649-650.

doi: 10.1001/jamaophthalmol.2017.1142.

¹ Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts2Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts3CME Editor, JAMA Ophthalmology.

No abstract available

Comment on

Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, King J, Antoszyk AN, Peters MA, Tolentino M; SCORE2 Investigator Group. Scott IU, et al. JAMA Ophthalmol. 2017 Jun 1;135(6):639-649. doi: 10.1001/jamaophthalmol.2017.1141. JAMA Ophthalmol. 2017. PMID: 28492860 Free PMC article. Clinical Trial.